Methylprednisolone pharmacokinetics?

Here’s a concise overview of methylprednisolone pharmacokinetics. Values vary by formulation (oral, IV, IM depot, etc.) and by route, but these are the typical/general features.

- Identity and formulations
- Synthetic glucocorticoid.
- Available as oral tablets, methylprednisolone sodium succinate (water-soluble for IV/IM use), and methylprednisolone acetate (depot IM).

- Absorption
- Oral: high bioavailability, roughly 89–95%; peak plasma levels in about 1–2 hours (varies with food and GI factors).
- IV: immediate bioavailability (drug reaches systemic circulation immediately).
- Depot: methylprednisolone acetate is slowly released from the injection site, producing prolonged exposure.

- Distribution
- Widely distributed; crosses the placenta and, to some extent, the blood–brain barrier.
- Protein binding: about 77–88% bound to plasma proteins (corticosteroid-binding globulin and albumin).
- Volume of distribution (Vd): roughly 0.4–1.0 L/kg (reflects substantial tissue distribution).

- Metabolism
- Primarily hepatic metabolism.
- Metabolized to inactive metabolites (glucuronide and sulfate conjugates; CYP3A4 involvement in oxidation steps).
- Metabolic rate can be influenced by liver function and drug interactions.

- Elimination and half-life
- Terminal (plasma) half-life: typically about 18–36 hours.
- Biological/clinical duration of action tends to be longer than the terminal half-life (often 1–2 days for anti-inflammatory effects, longer with depot forms).
- Excretion: metabolites excreted mainly in urine (renal elimination of conjugates).

- Special formulation-related PK
- Methylprednisolone sodium succinate (IV/IM): rapid onset; used for acute treatment.
- Methylprednisolone acetate (depot IM): slow, prolonged release (weeks to a month or more, depending on dose and site).

- Special populations and drug interactions
- Hepatic impairment may reduce clearance; dosing adjustments may be needed.
- CYP3A4 inducers (e.g., rifampin) can decrease levels; inhibitors (e.g., ketoconazole) can increase levels.
- In pregnancy, crosses the placenta; use only if clearly needed and after risk–benefit assessment.

If you want, I can tailor this to a specific route (oral vs IV), a particular formulation (sodium succinate vs acetate), or a patient population (pediatric, hepatic impairment, etc.) and provide more exact numbers.